期刊文献+

姜黄素联合顺铂对人卵巢癌细胞株SKOV_3细胞增殖的抑制作用 被引量:1

Proliferation-inhibiting effect of curcumin combined with cisplatin on human ovarian cancer SKOV_3 cells in vitro
下载PDF
导出
摘要 目的探讨姜黄素及其联合顺铂对体外培养人卵巢癌细胞株SKOV3增殖的抑制作用。方法将培养的人卵巢癌SKOV3细胞分别单独(姜黄素组或顺铂组)及联合(姜黄素与顺铂联用组)加入不同浓度姜黄素(5、10、20、40μmol/L)、顺铂(2.5 mg/L)作用后,采用四甲基偶氮唑盐比色法(MTT法)检测SKOV3细胞增殖情况。结果不同浓度姜黄素组随着药物浓度增加、作用时间延长,细胞的增殖抑制率上升,差异有统计学意义(P<0.05);联合用药组明显高于单一用药组(P<0.05),两药联合应用具有协同作用。结论姜黄素对卵巢癌SKOV3细胞增殖具有抑制作用,在一定范围内,这种抑制作用呈剂量-时间依赖性;姜黄素与顺铂联合应用具有协同作用,可提高SKOV3细胞对顺铂的敏感性,是一种理想的化疗增敏剂。 Objective To investigate the proliferation-inhibiting effect of curcumin and curcumin combined with cisplatin on human ovarian cancer cell line SKOV3 in vitro. Methods Human ovarian cancer SKOV3 cells were cultured and treated with different concentrations of eurcumin (5,10,20,40 μmol/L), cisplatin (2.5 mg/L), or curcumin combined with eisplatin in different concentrations. The proliferation of SKOV3 ceils was detected by MTT assay. Results MTT assay showed that curcumin with different concentrations could significantly inhibit the proliferation of SKOV3 cells in time-dependent and dose-dependent manners (P〈0.05). Compared with that in single drug groups, the inhibition effect in the combination treatment group was significantly higher(P〈0.05) ,showing the synergic effect. Conclusion Curcumin can inhibit the proliferation of SKOV3 ceils. In a certain range, the effect is in dose- and time-dependent manners. Curcumin combined with cisplatin has the synergistic effect can inrease the SKOV3 cell's sensitivity to cisptin, and is an ideal sensitivity-increasing agent for chemotherapy.
出处 《现代医药卫生》 2012年第23期3523-3524,共2页 Journal of Modern Medicine & Health
基金 川北医学院附属医院科研基金资助项目(2010-院内-11)
关键词 姜黄素 顺铂 卵巢肿瘤 卵巢癌SKOV3细胞株 细胞增殖 Curcumin Cisplatin Ovarian neoplasms Ovarian cancer SKOV3 cell Cell proliferation
  • 相关文献

参考文献10

二级参考文献31

  • 1欧阳一芹,李怀芳.多药耐药与卵巢癌化疗研究进展[J].同济大学学报(医学版),2006,27(B09):60-62. 被引量:1
  • 2马丁.卵巢癌多药耐药机制的探讨[J].中华妇幼临床医学杂志(电子版),2007,3(4):184-188. 被引量:6
  • 3Kaur T, Slavcev RA, Wettig SD. Addressing the challenge : current and future directions in ovarian cancer therapy [ J ]. Curt Gene T- her, 2009,9(6) :434-458. 被引量:1
  • 4Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the Pharmacokinetics of anti-cancer drug [J]. Eur J Pharm Sci, 2000,11(4) :265-283. 被引量:1
  • 5Zhang T, GuanM, Jin HY, et al. Reversal of muhidrug resistance by small interfering double-stranded RNAs in ovarian cancer cells [ J ]. Gynecol Oncol, 2005,97 ( 2 ) :501-507. 被引量:1
  • 6Shabbits JA, Mayer LD. P-glycop rotein modulates ceramide-medi- atedsensitivity of human breast cancer cells to tubulin-binding anti- cancer drugs[ J]. Mol Cancer Ther, 2002,1 (3) :205. 被引量:1
  • 7Jia P, Wu S, Li F, et al. Breast cancer resistance protein-media- ted topotecan resistance in ovarian cancer cells [ J ]. Int J Gynecol Cancer, 2005,15(6) :1042-1048. 被引量:1
  • 8Izquierdo MA, Scheffer GL, Fleus M J, et al. Major vault protein LRP-related multidrug resistance[J].Eur Cancer, 1996,32 ( 6 ) : 979-994. 被引量:1
  • 9Izquierdo MA, Van Zee AG. Drug marker LRP for prediction of response to chemotherapy and prognoses in ad- vanced ovarian carcinoma[J]. J Natel Cancer Inst, 1995,87(16) : 1230-1237. 被引量:1
  • 10Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nu- cleotide RNAs mediate RNA interference in cul-tur ed mammalian cells[J]. Nature, 2001,411 (6836) :494-498. 被引量:1

共引文献106

同被引文献2

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部